Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$0.75 /

-0.3398 (-31.17%)

05:13
10/12/20
10/12
05:13
10/12/20
05:13

Mallinckrodt voluntarily initiates Chapter 11 proceedings in bankruptcy court

Mallinckrodt announced that it has voluntarily initiated Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware to modify its capital structure, including restructuring portions of its debt, and resolve several billion dollars of potential legal liabilities. Mallinckrodt and all of its subsidiaries are continuing to operate and supply customers and patients with products as normal. The entities that filed Chapter 11 petitions include Mallinckrodt, substantially all of its U.S. subsidiaries, including its specialty generics-focused subsidiaries and specialty brands-related subsidiaries, and certain of its international subsidiaries. The company intends to use the Chapter 11 process to provide a mechanism to implement a restructuring support agreement, or RSA, that, among other things, provides for an amended proposed opioid claims settlement and a financial restructuring that would: reduce the company's total debt by approximately $1.3B; resolve opioid-related claims against the company, its subsidiaries and related entities; and resolve various Acthar Gel-related matters, including the CMS Medicaid rebate dispute, an associated False Claims Act, or FCA, lawsuit and an FCA lawsuit relating to Acthar's previous owner's interactions with an independent charitable foundation. In connection with the Chapter 11 filing, the company has entered into an RSA that provides for a financial restructuring designed to strengthen the company's balance sheet and reduce its total debt by approximately $1.3B. Parties to the RSA include: Holders of approximately 84% of the company's guaranteed unsecured notes; 50 states and territories; and the court-appointed plaintiffs' executive committee representing the interests of thousands of plaintiffs in the opioid multidistrict litigation, or Opioid MDL, which has agreed to recommend that the more than 1,000 counties, municipalities, Native American tribes and other opioid claimants in the Opioid MDL support the RSA. Under the terms of the RSA, at the end of the court-supervised process: all allowed first lien credit agreement claims, first lien note claims and second lien note claims are expected to be reinstated at existing rates and maturities; holders of allowed guaranteed unsecured note claims are expected to receive their pro rata share of $375M of new secured second lien notes due seven years after emergence and 100% of new Mallinckrodt ordinary shares, subject to dilution by the warrants described below and certain other equity; trade creditors and holders of allowed general unsecured claims are expected to share in $150M in cash and equity holders and non-guaranteed unsecured noteholders are expected to receive no recovery. The company has reached an agreement in principle on the terms of an amended proposed settlement that would resolve opioid-related claims against Mallinckrodt and its subsidiaries and eliminate billions of dollars in alleged liabilities. The amended proposed settlement is supported by a broad array of opioid plaintiffs as detailed above. Under the terms of the amended proposed settlement, which would become effective upon Mallinckrodt's emergence from the Chapter 11 process, subject to court approval and other conditions: opioid claims would be channeled to one or more trusts, which would receive $1.6B in structured payments. A total of $450M would be received upon the company's emergence from Chapter 11; $200M would be received on each of the first and second anniversaries of emergence, and $150M would be received on each of the third through seventh anniversaries of emergence with a one-year prepayment option at a discount for all but the first payment. Opioid claimants would also receive warrants for approximately 19.99% of the Company's fully diluted outstanding shares, including after giving effect to the exercise of the warrants, exercisable at a strike price reflecting an aggregate equity value of $1.551B. Upon commencing the Chapter 11 filing, the company will comply with an agreed-upon operating injunction with respect to the operation of its opioid business. Mallinckrodt has reached an agreement in principle with certain governmental parties to resolve certain disputes relating to Acthar Gel. The agreement in principle is conditioned upon Mallinckrodt entering the Chapter 11 restructuring process. The company has agreed to pay $260M over seven years and reset Acthar Gel's Medicaid rebate calculation as of July 1, such that state Medicaid programs will receive 100% rebates on Acthar Gel Medicaid sales, based on current Acthar Gel pricing. Additionally, upon execution of the settlement, the company will dismiss its appeal of the CMS Medicaid rebate ruling currently pending in the U.S. Court of Appeals for the D.C. Circuit. The settlement would resolve the CMS Medicaid rebate dispute, the associated FCA lawsuit in Boston and an FCA lawsuit in the Eastern District of Pennsylvania relating to Acthar's previous owner's interactions with an independent charitable foundation. Mallinckrodt expects to complete the settlement over the next several months, subject to bankruptcy court approval. The current consolidated cash balance of the Chapter 11 filing entities is more than $650M. Together with cash generated from ongoing operations, this is expected to provide ample liquidity to support continued operations during the court-supervised process. The company has filed a number of customary motions seeking court authorization to continue to support its business operations during the court-supervised process, including the continued payment of employee wages and benefits without interruption. The company intends to pay vendors and suppliers in full under normal terms for goods received and services rendered on or after the filing date. The company expects to receive court approval for all of these routine requests. The company's foreign non-debtor affiliates will continue to operate their businesses in the ordinary course. Separating the specialty generics and specialty brands businesses remains one of Mallinckrodt's goals. The company will continue to evaluate strategic options for the Specialty Generics business at an appropriate time and when market conditions are favorable.

  • 02

    Feb

MNK Mallinckrodt
$0.75 /

-0.3398 (-31.17%)

08/06/20 Citi
Mallinckrodt price target lowered to $1 from $2 at Citi
08/05/20 BMO Capital
Mallinckrodt price target lowered to $2 from $4 at BMO Capital
08/04/20 Piper Sandler
Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital

TODAY'S FREE FLY STORIES

Recommendations
Enagas price target raised to EUR 16 from EUR 15.75 at Morgan Stanley » 13:21
02/24/21
02/24
13:21
02/24/21
13:21
ENGGY

Enagas

$0.00 /

+ (+0.00%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ENGGY Enagas
$0.00 /

+ (+0.00%)

02/23/21 JPMorgan
Enagas upgraded to Neutral from Underweight at JPMorgan
02/12/21 UBS
Enagas initiated with a Neutral at UBS
02/09/21 Grupo Santander
Enagas downgraded to Hold from Buy at Grupo Santander
02/03/21 Barclays
Enagas price target lowered to EUR 18.10 from EUR 18.90 at Barclays
Technical Analysis
NASDAQ market internals summary » 13:17
02/24/21
02/24
13:17
02/24/21
13:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
$0.00 /

+ (+0.00%)

Technical Analysis
NYSE market internals summary » 13:16
02/24/21
02/24
13:16
02/24/21
13:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
$0.00 /

+ (+0.00%)

General news
5-Yr Note Auction Coupon Rate data reported » 13:10
02/24/21
02/24
13:10
02/24/21
13:10

5-Yr Note Auction Coupon…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
5-Yr Note Auction Total Amount data reported » 13:10
02/24/21
02/24
13:10
02/24/21
13:10

5-Yr Note Auction Total…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
Orbcomm price target raised to $9.25 from $7.50 at Roth Capital » 13:09
02/24/21
02/24
13:09
02/24/21
13:09
ORBC

Orbcomm

$8.02 /

+0.405 (+5.32%)

Roth Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ORBC Orbcomm
$8.02 /

+0.405 (+5.32%)

ORBC Orbcomm
$8.02 /

+0.405 (+5.32%)

12/21/20 Northland
Orbcomm price target raised to $10 from $6 at Northland
07/30/20 Roth Capital
Orbcomm price target raised to $7.50 from $7 at Roth Capital
02/27/20 Roth Capital
Orbcomm valuation, fundamentals should provide support, says Roth Capital
ORBC Orbcomm
$8.02 /

+0.405 (+5.32%)

Recommendations
Credit Agricole price target raised to EUR 13 from EUR 11.50 at RBC Capital » 13:09
02/24/21
02/24
13:09
02/24/21
13:09
CRARY

Credit Agricole

$0.00 /

+ (+0.00%)

RBC Capital analyst Anke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRARY Credit Agricole
$0.00 /

+ (+0.00%)

CRARY Credit Agricole
$0.00 /

+ (+0.00%)

05:09 Today JPMorgan
Credit Agricole upgraded to Overweight from Neutral at JPMorgan
02/18/21 AlphaValue
Credit Agricole upgraded to Add from Sell at AlphaValue
02/12/21 Morgan Stanley
Credit Agricole price target raised to EUR 13.10 at Morgan Stanley
01/22/21 Barclays
Credit Agricole upgraded to Overweight from Equal Weight at Barclays
Recommendations
TUI AG price target raised to 170 GBp from 68 GBp at UBS » 13:08
02/24/21
02/24
13:08
02/24/21
13:08
TUIFY

TUI AG

$0.00 /

+ (+0.00%)

UBS analyst Cristian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TUIFY TUI AG
$0.00 /

+ (+0.00%)

02/12/21 Berenberg
TUI AG price target lowered to 175 GBp from 250 GBp at Berenberg
01/27/21 Commerzbank
TUI AG downgraded to Reduce from Hold at Commerzbank
01/26/21 HSBC
TUI AG downgraded to Reduce from Hold at HSBC
12/21/20 Berenberg
TUI AG price target lowered to 250 GBp from 350 GBp at Berenberg
Recommendations
Skanska price target raised to SEK 178 from SEK 172 at UBS » 13:07
02/24/21
02/24
13:07
02/24/21
13:07
SKSBF

Skanska

$0.00 /

+ (+0.00%)

UBS analyst Anastasia…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SKSBF Skanska
$0.00 /

+ (+0.00%)

SKSBF Skanska
$0.00 /

+ (+0.00%)

02/10/21 BofA
Skanska downgraded to Underperform from Neutral at BofA
11/20/20 UBS
Skanska price target raised to SEK 172 from SEK 160 at UBS
06/08/20 BofA
Skanska upgraded to Neutral from Underperform at BofA
05/14/20 UBS
Skanska price target lowered to SEK 160 from SEK 175 at UBS
Recommendations
HeidelbergCement price target raised to EUR 73 from EUR 71.50 at UBS » 13:06
02/24/21
02/24
13:06
02/24/21
13:06
HDELY

HeidelbergCement

$0.00 /

+ (+0.00%)

UBS analyst Gregor…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HDELY HeidelbergCement
$0.00 /

+ (+0.00%)

02/04/21 Goldman Sachs
HeidelbergCement downgraded to Sell from Neutral at Goldman Sachs
01/26/21 Deutsche Bank
HeidelbergCement price target raised to EUR 82 from EUR 77 at Deutsche Bank
01/22/21 JPMorgan
HeidelbergCement price target lowered to EUR 68 from EUR 70 at JPMorgan
01/20/21 Barclays
HeidelbergCement price target raised to EUR 74 from EUR 64 at Barclays
Recommendations
Eni SpA price target raised to EUR 11.75 from EUR 11.50 at UBS » 13:05
02/24/21
02/24
13:05
02/24/21
13:05
E

Eni SpA

$23.35 /

+0.21 (+0.91%)

UBS analyst Jon Rigby…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
E Eni SpA
$23.35 /

+0.21 (+0.91%)

02/23/21 Berenberg
Eni SpA price target raised to EUR 10 from EUR 9 at Berenberg
02/23/21 DZ Bank
Eni SpA upgraded to Hold from Sell at DZ Bank
02/22/21 RBC Capital
Eni SpA upgraded to Sector Perform from Underperform at RBC Capital
02/22/21 RBC Capital
Eni SpA upgraded to Sector Perform from Underperform at RBC Capital
Options
Applied Materials call volume above normal and directionally bullish » 13:05
02/24/21
02/24
13:05
02/24/21
13:05
AMAT

Applied Materials

$120.07 /

+4.19 (+3.62%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMAT Applied Materials
$120.07 /

+4.19 (+3.62%)

AMAT Applied Materials
$120.07 /

+4.19 (+3.62%)

02/19/21 DA Davidson
Applied Materials price target raised to $145 from $135 at DA Davidson
02/19/21 JPMorgan
Applied Materials price target raised to $146 from $88 at JPMorgan
02/19/21 Craig-Hallum
Applied Materials price target raised to $142 from $124 at Craig-Hallum
02/19/21 Evercore ISI
Applied Materials price target raised to $140 from $130 at Evercore ISI
AMAT Applied Materials
$120.07 /

+4.19 (+3.62%)

AMAT Applied Materials
$120.07 /

+4.19 (+3.62%)

AMAT Applied Materials
$120.07 /

+4.19 (+3.62%)

AMAT Applied Materials
$120.07 /

+4.19 (+3.62%)

Hot Stocks
ViiV Healthcare submits sNDA to FDA for HIV treatment Cabenuva » 13:05
02/24/21
02/24
13:05
02/24/21
13:05
GSK

GlaxoSmithKline

$34.60 /

+0.23 (+0.67%)

, PFE

Pfizer

$33.81 /

-0.09 (-0.27%)

ViiV Healthcare, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GSK GlaxoSmithKline
$34.60 /

+0.23 (+0.67%)

PFE Pfizer
$33.81 /

-0.09 (-0.27%)

GSK GlaxoSmithKline
$34.60 /

+0.23 (+0.67%)

02/12/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,580 GBp at Morgan Stanley
02/11/21 Berenberg
GlaxoSmithKline price target lowered to 1,570 GBp from 1,720 GBp at Berenberg
02/09/21 JPMorgan
GlaxoSmithKline price target lowered to 1,300 GBp from 1,500 GBp at JPMorgan
02/08/21 UBS
GlaxoSmithKline price target lowered to 1,320 GBp from 1,450 GBp at UBS
PFE Pfizer
$33.81 /

-0.09 (-0.27%)

02/23/21 B. Riley Securities
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
GSK GlaxoSmithKline
$34.60 /

+0.23 (+0.67%)

PFE Pfizer
$33.81 /

-0.09 (-0.27%)

GSK GlaxoSmithKline
$34.60 /

+0.23 (+0.67%)

PFE Pfizer
$33.81 /

-0.09 (-0.27%)

GSK GlaxoSmithKline
$34.60 /

+0.23 (+0.67%)

PFE Pfizer
$33.81 /

-0.09 (-0.27%)

GSK GlaxoSmithKline
$34.60 /

+0.23 (+0.67%)

PFE Pfizer
$33.81 /

-0.09 (-0.27%)

Hot Stocks
Walgreens says Pixel by Labcorp COVID-19 PCR test to be available OTC nationwide » 13:03
02/24/21
02/24
13:03
02/24/21
13:03
WBA

Walgreens Boots Alliance

$48.98 /

+0.56 (+1.16%)

, LH

LabCorp

$243.40 /

-3.83 (-1.55%)

Walgreens (WBA) has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$48.98 /

+0.56 (+1.16%)

LH LabCorp
$243.40 /

-3.83 (-1.55%)

WBA Walgreens Boots Alliance
$48.98 /

+0.56 (+1.16%)

01/27/21 Deutsche Bank
Walgreens Boots Alliance price target raised to $49 from $44 at Deutsche Bank
01/15/21 Baird
Walgreens Boots Alliance price target raised to $64 from $55 at Baird
01/11/21
Fly Intel: Top five analyst upgrades
01/11/21 Baird
Baird upgrades Walgreens Boots Alliance following Q1 results
LH LabCorp
$243.40 /

-3.83 (-1.55%)

02/12/21 JPMorgan
LabCorp price target raised to $279 from $261 at JPMorgan
02/12/21 Mizuho
LabCorp price target raised to $267 from $242 at Mizuho
02/12/21 Citi
LabCorp price target raised to $278 from $257 at Citi
01/29/21 Citi
LabCorp price target raised to $257 from $249 at Citi
WBA Walgreens Boots Alliance
$48.98 /

+0.56 (+1.16%)

LH LabCorp
$243.40 /

-3.83 (-1.55%)

WBA Walgreens Boots Alliance
$48.98 /

+0.56 (+1.16%)

LH LabCorp
$243.40 /

-3.83 (-1.55%)

WBA Walgreens Boots Alliance
$48.98 /

+0.56 (+1.16%)

LH LabCorp
$243.40 /

-3.83 (-1.55%)

WBA Walgreens Boots Alliance
$48.98 /

+0.56 (+1.16%)

LH LabCorp
$243.40 /

-3.83 (-1.55%)

Hot Stocks
Carnival extends pause from U.S. through May 2021 » 13:02
02/24/21
02/24
13:02
02/24/21
13:02
CCL

Carnival

$27.50 /

+1.04 (+3.93%)

Carnival Cruise Line has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CCL Carnival
$27.50 /

+1.04 (+3.93%)

CCL Carnival
$27.50 /

+1.04 (+3.93%)

02/12/21 Berenberg
Carnival downgraded to Sell from Hold at Berenberg
01/26/21 HSBC
Carnival downgraded to Reduce from Hold at HSBC
01/22/21 Truist
Carnival price target raised to $14 from $11 at Truist
01/12/21 Deutsche Bank
Carnival price target raised to $16 from $13 at Deutsche Bank
  • 23
    Feb
  • 02
    Apr
CCL Carnival
$27.50 /

+1.04 (+3.93%)

CCL Carnival
$27.50 /

+1.04 (+3.93%)

CCL Carnival
$27.50 /

+1.04 (+3.93%)

Syndicate
Mogo announces closing of $54M registered direct offering priced at-the-market » 13:01
02/24/21
02/24
13:01
02/24/21
13:01
MOGO

Mogo

$8.13 /

+1.02 (+14.35%)

Mogo announced that it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MOGO Mogo
$8.13 /

+1.02 (+14.35%)

MOGO Mogo
$8.13 /

+1.02 (+14.35%)

02/11/21 Canaccord
Mogo downgraded to Hold from Speculative Buy at Canaccord
01/08/21 Raymond James
Mogo price target raised to C$7.50 from C$4.50 at Raymond James
12/01/20 Raymond James
Mogo price target raised to C$4.50 from C$4 at Raymond James
11/23/20 H.C. Wainwright
Mogo initiated with a Buy at H.C. Wainwright
Recommendations
Rightmove price target raised to 600 GBp from 540 GBp at Deutsche Bank » 13:01
02/24/21
02/24
13:01
02/24/21
13:01
RTMVY

Rightmove

$0.00 /

+ (+0.00%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RTMVY Rightmove
$0.00 /

+ (+0.00%)

02/04/21 UBS
Rightmove price target raised to 630 GBp from 620 GBp at UBS
01/29/21 Barclays
Rightmove price target lowered to 550 GBp from 575 GBp at Barclays
01/20/21 BofA
Rightmove downgraded to Underperform from Neutral at BofA
01/12/21 Berenberg
Rightmove price target raised to 440 GBp from 400 GBp at Berenberg
Recommendations
InterContinental price target lowered to 5,380 GBp at Deutsche Bank » 12:59
02/24/21
02/24
12:59
02/24/21
12:59
IHG

InterContinental

$73.13 /

-0.92 (-1.24%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IHG InterContinental
$73.13 /

-0.92 (-1.24%)

IHG InterContinental
$73.13 /

-0.92 (-1.24%)

05:11 Today Deutsche Bank
InterContinental downgraded to Hold from Buy at Deutsche Bank
02/22/21 Peel Hunt
InterContinental downgraded to Reduce from Hold at Peel Hunt
02/18/21 Morgan Stanley
InterContinental price target raised to 4,600 GBp from 4,300 GBp at Morgan Stanley
02/12/21 Berenberg
InterContinental price target raised to 4,500 GBp from 4,000 GBp at Berenberg
Recommendations
Covestro price target raised to EUR 76 from EUR 65 at Deutsche Bank » 12:58
02/24/21
02/24
12:58
02/24/21
12:58
COVTY

Covestro

$0.00 /

+ (+0.00%)

Deutsche Bank analyst Tim…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
COVTY Covestro
$0.00 /

+ (+0.00%)

01/13/21 Berenberg
Covestro price target raised to EUR 60 from EUR 47 at Berenberg
01/12/21 Barclays
Covestro price target raised to EUR 64 from EUR 53 at Barclays
12/17/20 UBS
Covestro price target raised to EUR 45 from EUR 41 at UBS
12/14/20 Morgan Stanley
Covestro price target raised to EUR 60 from EUR 55 at Morgan Stanley
COVTY Covestro
$0.00 /

+ (+0.00%)

General news
Fed Chair Powell is pushing back against criticism that the Fed's QE purchases » 12:55
02/24/21
02/24
12:55
02/24/21
12:55

Fed Chair Powell is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
Marcus & Millichap to host virtual investor meeting » 12:55
02/24/21
02/24
12:55
02/24/21
12:55
MMI

Marcus & Millichap

$39.48 /

-0.06 (-0.15%)

Virtual Investor Meeting…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MMI Marcus & Millichap
$39.48 /

-0.06 (-0.15%)

MMI Marcus & Millichap
$39.48 /

-0.06 (-0.15%)

04/09/20 Wells Fargo
Marcus & Millichap downgraded at Wells Fargo on declining transaction volume
04/09/20 Wells Fargo
Marcus & Millichap downgraded to Underweight from Equal Weight at Wells Fargo
MMI Marcus & Millichap
$39.48 /

-0.06 (-0.15%)

MMI Marcus & Millichap
$39.48 /

-0.06 (-0.15%)

Syndicate
American National Bankshares files $75M mixed securities shelf  12:54
02/24/21
02/24
12:54
02/24/21
12:54
AMNB

American National Bankshares

$31.17 /

+0.92 (+3.04%)

 
ShowHide Related Items >><<
AMNB American National Bankshares
$31.17 /

+0.92 (+3.04%)

AMNB American National Bankshares
$31.17 /

+0.92 (+3.04%)

04/29/20 Stephens
American National Bankshares upgraded to Overweight from Equal Weight at Stephens
AMNB American National Bankshares
$31.17 /

+0.92 (+3.04%)

Upgrade
Barrington upgrades Heidrick & Struggles to Outperform, sees continued recovery » 12:50
02/24/21
02/24
12:50
02/24/21
12:50
HSII

Heidrick & Struggles

$37.36 /

+1.08 (+2.98%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HSII Heidrick & Struggles
$37.36 /

+1.08 (+2.98%)

HSII Heidrick & Struggles
$37.36 /

+1.08 (+2.98%)

12:47 Today Barrington
Heidrick & Struggles upgraded to Outperform from Market Perform at Barrington
02/23/21 Truist
Heidrick & Struggles price target raised to $40 from $25 at Truist
04/29/20 Barrington
Heidrick & Struggles downgraded to Market Perform from Outperform at Barrington
HSII Heidrick & Struggles
$37.36 /

+1.08 (+2.98%)

HSII Heidrick & Struggles
$37.36 /

+1.08 (+2.98%)

Upgrade
Heidrick & Struggles upgraded to Outperform from Market Perform at Barrington » 12:47
02/24/21
02/24
12:47
02/24/21
12:47
HSII

Heidrick & Struggles

$37.36 /

+1.08 (+2.98%)

Barrington analyst Kevin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HSII Heidrick & Struggles
$37.36 /

+1.08 (+2.98%)

HSII Heidrick & Struggles
$37.36 /

+1.08 (+2.98%)

02/23/21 Truist
Heidrick & Struggles price target raised to $40 from $25 at Truist
04/29/20 Barrington
Heidrick & Struggles downgraded to Market Perform from Outperform at Barrington
HSII Heidrick & Struggles
$37.36 /

+1.08 (+2.98%)

HSII Heidrick & Struggles
$37.36 /

+1.08 (+2.98%)

Options
Halliburton call volume above normal and directionally bullish » 12:45
02/24/21
02/24
12:45
02/24/21
12:45
HAL

Halliburton

$22.19 /

+1.25 (+5.97%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HAL Halliburton
$22.19 /

+1.25 (+5.97%)

HAL Halliburton
$22.19 /

+1.25 (+5.97%)

02/01/21
Fly Intel: Top five analyst upgrades
02/01/21 Piper Sandler
Halliburton upgraded to Overweight from Neutral at Piper Sandler
01/27/21 Evercore ISI
Evercore upgrades NexTier Oilfield to Outperform on tightening market conditions
01/25/21 Atlantic Equities
Halliburton upgraded to Overweight from Neutral at Atlantic Equities
HAL Halliburton
$22.19 /

+1.25 (+5.97%)

HAL Halliburton
$22.19 /

+1.25 (+5.97%)

HAL Halliburton
$22.19 /

+1.25 (+5.97%)

HAL Halliburton
$22.19 /

+1.25 (+5.97%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.